Biomarker Testing & Analytics + Hormone Optimisation
Documented synergy between Biomarker Testing & Analytics and Hormone Optimisation. Canonical combination in literature · see protocol and evidence.
View comparison →Know your true biology and make informed decisions
Definition and how it works: Advanced biomarker analytics go far beyond routine blood tests. They include inflammation panels (high-sensitivity CRP, IL-6, TNF-α), energy metabolism (NAD+, mitochondrial ATP), comprehensive hormones, biological ageing markers (telomeres, DNA methylation — Horvath epigenetic clocks), gut microbiome, toxic exposome (heavy metals, endocrine disruptors) and over 100 parameters that provide a complete picture of your true health status.
Advanced biomarker analytics go far beyond routine blood tests. They include inflammation panels (high-sensitivity CRP, IL-6, TNF-α), energy metabolism (NAD+, mitochondrial ATP), comprehensive hormones, biological ageing markers (telomeres, DNA methylation — Horvath epigenetic clocks), gut microbiome, toxic exposome (heavy metals, endocrine disruptors) and over 100 parameters that provide a complete picture of your true health status.
Origin and history
The concept of routine biochemical analysis dates back to the 19th century. Longevity biomarkers emerged as a discipline with the discovery of CRP protein in 1930 and accelerated with 21st-century genomics and epigenomics. The first epigenetic clock was published by Steve Horvath in 2013.
1. Panel design Consultation with a longevity specialist. Marker selection based on goals and medical history.
2. Patient preparation 10–12 hour fast. No alcohol for 48 hours. No intense exercise for the prior 24 hours.
3. Sample collection Venous blood, 24-hour urine and stool sample (microbiome). Sent to a specialised laboratory.
4. Analysis and interpretation Panel of >100 markers. Epigenetic clock. Personalised report with optimal ranges.
5. Action plan Interpretation consultation. Design of an intervention protocol based on results.
| Equipment | Brand / Model | Technical detail |
|---|---|---|
| Multiparameter analyser | Roche Cobas / Abbott Alinity | Simultaneous biochemistry, hormonal and inflammation analysis. ISO 15189. |
| Epigenetic clock kit | TruDiagnostic / Chronomics / Elysium Index | DNA methylation at >1 million loci. DunedinPACE, GrimAge, Horvath. |
Clinics on LongevityMap declare their exact equipment for objective scoring.
Know your true biology and make informed decisions
€200–2,000 (varies by panel scope)
Initial comprehensive panel + six-monthly or annual follow-up
Prices vary by clinic, equipment and practitioner experience. LongevityMap compares price and quality so you always make the best decision.
Documented synergy between Biomarker Testing & Analytics and Hormone Optimisation. Canonical combination in literature · see protocol and evidence.
View comparison →Documented synergy between Biomarker Testing & Analytics and NAD+ IV Therapy. Canonical combination in literature · see protocol and evidence.
View comparison →Documented synergy between Biomarker Testing & Analytics and Peptide Therapy. Canonical combination in literature · see protocol and evidence.
View comparison →We are collecting signed consents under GDPR Art. 9.2.a. First verified testimonials will appear once the first real clinics are onboarded (Q4 2026).
Epigenetic clocks (Horvath 2013, PhenoAge, GrimAge, DunedinPACE) measure DNA methylation at specific loci to estimate biological age with 1–3 year accuracy. Studies in Nature Aging confirm that reductions in epigenetic age correlate with lower all-cause mortality. Advanced biomarker panels can detect cardiovascular risk up to 10 years earlier than conventional methods.
2026 study (Multiethnic Cohort): GrimAge epigenetic acceleration predicted lung cancer risk (HR 1.40; 95% CI 1.16-1.71) and all-cause mortality in smokers. DunedinPACE also predicted risk (HR 1.31). Solid clinical predictive validation.
2026 cohort (median 5.83-yr follow-up, cardiovascular-kidney-metabolic risk): PhenoAge acceleration is associated with all-cause mortality (HR 2.81 top vs bottom quartile) and cardiovascular mortality. Each 1-yr acceleration significantly elevates risk.
2026 double-blind placebo METFORAGING RCT (n=40, non-diabetic older adults with HIV): 96 weeks of metformin vs placebo to assess epigenetic age changes. 97.5% adherence. Study halted at n=40<60 target due to slow recruitment.
Aging Cell 2026 (multi-omics clocks review): organ biological clocks integrate genomic, epigenetic, transcriptomic, proteomic and metabolomic data. Different organs age at different rates, explaining variability in age-associated diseases. Clinical implementation still limited.
Last bibliographic review: 2026-03-28.
DunedinPACE (2022) is currently considered the most predictive of future mortality, as it measures the pace of ageing over the past year. GrimAge is the most validated in mortality studies. The original Horvath clock measures cumulative biological age.
Results should be interpreted by a physician specialising in precision or longevity medicine. They allow the design of a personalised intervention protocol (nutrition, supplementation, therapies) and objective progress tracking.
An initial comprehensive panel, followed by repetition of the most relevant parameters every 6–12 months to assess response to interventions. Epigenetic clocks are repeated annually.
Tell us your goal and budget. We cross-reference 500+ clinical parameters and generate 3 personalised plans with Biomarker Testing & Analytics.
Generate My Protocol for freeLongevityMap content is for informational and educational purposes only. It does not constitute personalised medical advice. Always consult a healthcare professional before starting any treatment. Our team · Methodology